bioAffinity Technologies, Inc. (BIAF): שווי פעילות לרווח לפני ריבית, מסים ופחת

bioAffinity Technologies (BIAF) is a pioneer in lung cancer detection via sputum analysis using cytometry. This chart of the asset's value on GURU.Markets captured the figure 0.00. The lack of painless alternatives grants the firm significant pricing power. The business is currently in the product implementation phase, meaning bioAffinity Technologies (BIAF) requires an influx of investment until it evolves into a stable cash cow.

The multiple is calculated as the ratio of enterprise value (EV) to earnings before interest, taxes, depreciation, and amortization, determining the payback period of assets inclusive of debt. The current EV/EBITDA value for bioAffinity Technologies (BIAF) on this chart is 0.00, which allows for an assessment of operating cash flow efficiency. The high precision of bioAffinity Technologies diagnostic tests creates pricing power that should maintain the stability of this metric even amidst market volatility.